Mariposa 2 Study

About The
MARIPOSA 2 Study

The MARIPOSA 2 Study is evaluating the safety and effectiveness of two investigational medications in addition to approved chemotherapy in adults with advanced or metastatic non-small-cell lung cancer (NSCLC). Participants in this study need to have one of two relatively common EGFR mutations: Exon 19 deletion or Exon 21 L858R substitution.

See If You Are Eligible

You may be able to take
part in the MARIPOSA 2 Study if you:

  • Are 18 years of age or older
  • Have been diagnosed with non-small-cell lung cancer that has tested positive for EGFR Exon 19 deletion or Exon 21 L858R substitution
  • Have experienced disease progression on or after taking osimertinib
Additional eligibility criteria will be assessed by the study doctor or staff during the screening process prior to you being enrolled in the study and receiving any investigational medication.

See If You Are Eligible

For additional information:

Download the MARIPOSA 2 Study brochure
What’s involved with study participation?

Participants in the MARIPOSA 2 Study will be randomly assigned to 1 of 3 study treatment groups. Each group will receive a different combination of investigational medications while completing various study tests and procedures.

  • The study duration will vary from person to person depending on the response to the investigational medications and subsequent medications.
  • Participants may leave the study at any point in time.
Does participating in this study cost me anything?

All study-required visits, tests, and medications will be provided at no cost to qualified participants. The study will not pay for other medical care or current medication(s) needed to support your daily healthcare routine. In addition, reimbursement for study-required travel, meals, and parking may be available.

If pre-qualified, what can I expect on my first visit to the study clinic? 

This initial appointment is an opportunity for you to:

  • Learn more about the MARIPOSA 2 Study. You’ll be speaking with a study doctor to learn more regarding your participation in this study.
  • Ask any important questions you may have. These can be any questions you may have about this study or clinical research in general.
  • Determine if the MARIPOSA 2 Study may be right for you. After speaking with the study doctor and learning details about this study, the study staff will perform a series of screening tests to determine if you are eligible to participate. If you are eligible, you and your doctor can then decide if this study is right for you. No tests for the actual study will be given at this time. If you agree to take part, the study staff will ask you to review and sign a consent form.
What can I expect if I join the study?

Participants in the study will be randomly assigned to 1 of 3 study treatment groups: study treatment Arm A, B, or C. Each group will receive a different combination of investigational medications.

  • In the study treatment period, each study treatment cycle will last 21 days. During the first day of each cycle (for Arms A and C, for the first cycle it will be the 1st and 2nd days), you will be infused with investigational medications. You will also take one daily investigational medication if you are in study treatment Arm A.
  • After the study treatment period, there will be follow-up visits every 12 weeks (your visits may be replaced with phone calls).
  • Qualified patients may receive investigational medications and some study-required care at no cost. The study will not pay for other medical care or current medication(s) needed to support your daily health care routine.
What if my condition worsens or I have side effects?

You should make sure to inform your doctor of any new symptoms you experience while participating in the study. If you experience worsening of your disease at any time during the study, your study doctor will ask you to come to the study clinic to determine disease progression. If your disease is progressing, you will be asked to complete an end of treatment visit 30 days after your last dose of investigational medications. You will then enter the follow-up period with visits to the study clinic or telephone contact every 12 weeks until the end of study to find out how you are doing, if you have had any side effects, and if you have started any new cancer treatments.

Where are the study clinics located?

There are study clinics located throughout the United States. Find a location near you.

To see a list of participating study clinics in over 20 countries globally, visit this page.

For additional information:

Download the MARIPOSA 2 Study brochure
Consider enrolling in this study today.
See If You Are Eligible
If you have EGFR-Positive Non-Small-Cell Lung Cancer, your journey may include a different path.

The more we learn, the farther we can go.